EVO

Evotec SEC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-09-20 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.55

Analysis reference price unavailable

Analysis 2026-09-20 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.80

Analysis reference price unavailable

Analysis 2026-09-20 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-20

AI commentary

The operating evidence remains mixed but tilted negative. A direct fetch of Evotec's August 13 company release confirmed weak H1 profitability and sharply reduced guidance, alongside stronger D&PD base-business activity, high Just–Evotec Biologics capacity utilization and initial Horizon savings [#PR-2026-08-13]. The ADR declined approximately 7.5% from the prior baseline's $1.73 reference to the September 18 anchor of $1.60, but the packet does not establish a specific causal headline. Comprehensive post-reset analyst revisions are unavailable. Social, options, short-interest and employee-sentiment coverage are also unavailable and should not be interpreted as neutral readings.

RankAlpha Sentiment Codex - 2026-09-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-05eventQ3/9M results test reduced guidanceMedium impact

Evotec's scheduled November 5 interim statement should show whether improved customer activity is converting into revenue and whether the reduced FY2026 outlook remains achievable. The company's August 13 release reported H1 revenue of €300.1 million, adjusted EBITDA of negative €42.7 million, and updated guidance of €570–610 million in revenue and negative €70–105 million in adjusted EBITDA [#PR-2026-08-13] [#IR-2026-11-05].

2026-12-31catalystCommercial momentum converts into reported revenueHigh impact

Evotec's August 13 company release said D&PD base-business net sales excluding strategic partnerships increased approximately 28% year over year in H1, while Just–Evotec Biologics benefited from high capacity utilization and customer-base expansion. Conversion into stronger H2 revenue would support stabilization, but management said the financial benefits would take time to materialize [#PR-2026-08-13].

2027-12-31catalystHorizon savings restore operating leverageHigh impact

Evotec's August 13 company release confirmed initial Horizon savings and an expected 2026 contribution of approximately 20–30% of the previously announced €75 million annual run-rate savings target, which is targeted by the end of 2027. Delivery alongside improved utilization could narrow losses, but the current EBITDA guidance makes execution proof essential [#PR-2026-08-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-20 • Updated nightlySource: Internal modelMethodology